The estimated Net Worth of David Dalvey is at least $3.86 Millón dollars as of 14 December 2023. David Dalvey owns over 7,940 units of Celcuity Inc stock worth over $3,496,500 and over the last 7 years David sold CELC stock worth over $368,441.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Dalvey CELC stock SEC Form 4 insiders trading
David has made over 3 trades of the Celcuity Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently David sold 7,940 units of CELC stock worth $116,559 on 14 December 2023.
The largest trade David's ever made was selling 10,000 units of Celcuity Inc stock on 7 December 2023 worth over $149,300. On average, David trades about 2,273 units every 1 days since 2017. As of 14 December 2023 David still owns at least 225,000 units of Celcuity Inc stock.
You can see the complete history of David Dalvey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's David Dalvey's mailing address?
David's mailing address filed with the SEC is 16305 36TH AVENUE NORTH, SUITE 100, MINNEAPOLIS, MN, 55446.
Insiders trading at Celcuity Inc
Over the last 7 years, insiders at Celcuity Inc have traded over $452,378 worth of Celcuity Inc stock and bought 317,370 units worth $2,387,116 . The most active insiders traders include Brian F. Sullivan, Richard Nigon y Polly A. Murphy. On average, Celcuity Inc executives and independent directors trade stock every 67 days with the average trade being worth of $147,164. The most recent stock trade was executed by Richard E Buller on 23 August 2024, trading 350 units of CELC stock currently worth $5,933.
What does Celcuity Inc do?
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
What does Celcuity Inc's logo look like?
Complete history of David Dalvey stock trades at Celcuity Inc
Celcuity Inc executives and stock owners
Celcuity Inc executives and other stock owners filed with the SEC include:
-
Dr. Lance G. Laing,
Co-Founder, Chief Science Officer, VP, Sec. & Director -
Brian F. Sullivan,
Co-Founder, Chairman & CEO -
Vicky Hahne,
Chief Financial Officer -
Igor Gorbatchevsky,
MD & VP of Clinical Devel. -
Dr. Arthur P. DeCillis M.D.,
Chief Medical Officer -
Bernhard Lampert Ph.D.,
Head of CMC -
Marie DeGayner Kuker,
Head of Regulatory -
Sheri Smith,
Acting Head of Clinical Operations -
Dr. John R. MacDonald Ph., Dabt,
Sr. VP of R&D -
Dr. Arthur P. DeCillis,
Chief Medical Officer -
Eric Lindquist,
Chief Bus. Officer -
Vicky Hahne,
Chief Financial Officer -
Richard Nigon,
Director -
David Dalvey,
Director -
Maureen Therese Cronin,
Director -
Leo Furcht,
Director -
Richard E Buller,
Director -
Polly A. Murphy,
Director -
Lance G. Laing,
Chief Science Officer -
Brian F. Sullivan,
Chief Executive Officer